Early Molecular Response ≤1% Has Strong Prognostic Impact for CML Patients That Switch to Second‐line Therapy with BCR‐ABL1 ≤10% and No Major Molecular Response
British journal of haematology（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined